Psychedelic Stocks Jump After Trump Order Speeds U.S. Review Path
Psychedelic-related stocks surged in premarket and early trading after President Donald Trump signed an executive order aimed at accelerating research, review, and patient access for psychedelic treatments for serious mental illness. The order directs the FDA to prioritize certain psychedelic drugs with Breakthrough Therapy designation through the Commissioner’s National Priority Vouchers and also expands some access pathways. At the same time, the administration said it would commit $50 million to ibogaine research.
Among the key movers, U.K.-based Compass Pathways rose sharply, while U.S.-listed AtaiBeckley and Definium Therapeutics also rallied, and Ireland-based GH Research posted strong gains. Reuters reported Compass up about 37% and AtaiBeckley up about 28%. In comparison, MarketWatch cited Compass up 42.3%, AtaiBeckley up 22.2%, GH Research up 16.9%, and Definium up 2.4%, showing a powerful sector-wide repricing after the policy announcement. Analysts also highlighted potential beneficiaries, including Japan’s Otsuka, Helus Pharma, and Reunion Neuroscience, as the new voucher framework could shorten review timelines from roughly 6–10 months to 1–2 months for eligible drugs.
Possible Market Effect: The order may extend momentum in psychedelic and neuro-psychiatry names by improving the regulatory narrative and pulling forward commercialization expectations. The biggest gains are still likely to remain concentrated in companies with late-stage pipelines or Breakthrough Therapy exposure, while volatility could stay high because the policy does not remove clinical, safety, or approval risk.
Source: The White House; Reuters; MarketWatch
